0R55.L
Bone Therapeutics SA [0R55.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0R55.L Stock Summary
In the News
0R55.L Financial details
Company Rating
-
Market Cap
4.8M
Income
-36.98M
Revenue
1000K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.09
EPS next Y
-
EPS next Q
-
EPS this Y
-63.2%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-60.94%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
13.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0249-0.189
52W High
-
52W Low
-
RSI
32
Rel Volume
142.14
Avg Volume
12.07K
Volume
1.72M
Perf Week
-50%
Perf Month
-66.67%
Perf Quarter
-87.01%
Perf Half Y
-89.13%
-
-
-
-
Beta
0.00797446
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.001
Change
0%
Company Profile
- Volume Average 12.07K
- Market Capitalization 4.8M
- Employee 20
- CEO Prof. François Rieger
- Headquarters Mont-Saint-Guibert,BE
- IPO Date 2022-10-26
-
Website
https://www.bonetherapeutics.com 
Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase I/IIa clinical trial for the treatment of delayed-union fractures and lumbar spinal fusion; and JTA-004, an intra-articular injectable that is in phase III clinical trial to treat osteoarthritic pain in the knee. Bone Therapeutics SA was incorporated in 2006 and is based in Mont-Saint-Guibert, Belgium.
